Masonic Cancer Center

A Comprehensive Cancer Center designated by the National Cancer Institute

Find a Clinical Trial

Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help
Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

  Sip Protocol

Masonic Cancer Research Center
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Back to Search Instructions

Protocol No. 2012CG091 Principal Investigator Greengard, Emily
Phase Phase I
Age Group Children Scope National
Secondary Protocol No. ADVL1212
Title COG ADVL1212 - A Phase I Study of Crizotinib in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma. ADVL1212 Study Chair: NIH COG Phase I Grant (UMCA097452) ADVL1212 - Pfizer No. WS2274618
Applicable Disease Sites Any Site
Drugs Involved CYCLOPHOSPHAMIDE (CYTOXAN, NEOSAR)
DEXRAZOXANE
DOXORUBICIN HYDROCHLORIDE (ADRIAMYCIN)
PF-02341066 (PF-02341066-004, Crizotinib)
TOPOTECAN
VINCRISTINE (ONCOVIN)
Status Open
Participating Institutions Masonic Cancer Center
Treatment Type Treatment
Contact Jodelle Dahl Phone:612-625-2994
Email:jdahl@umphysicians.umn.edu
  • ©2013 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on